Alignment Healthcare, Inc. (NASDAQ:ALHC) CEO John E. Kao Sells 90,000 Shares

Alignment Healthcare, Inc. (NASDAQ:ALHC) CEO John E. Kao sold 90,000 shares of the company’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $14.23, for a total transaction of $1,280,700.00. Following the completion of the sale, the chief executive officer now directly owns 2,183,100 shares of the company’s stock, valued at $31,065,513. The trade was a 3.96 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Alignment Healthcare Stock Performance

ALHC stock traded up $0.14 during midday trading on Wednesday, hitting $14.52. The stock had a trading volume of 994,579 shares, compared to its average volume of 1,842,446. The firm has a market capitalization of $2.78 billion, a price-to-earnings ratio of -18.86 and a beta of 1.50. Alignment Healthcare, Inc. has a 52 week low of $4.46 and a 52 week high of $15.82. The stock has a 50-day simple moving average of $12.84 and a 200 day simple moving average of $11.52. The company has a current ratio of 1.60, a quick ratio of 1.60 and a debt-to-equity ratio of 1.82.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ALHC. R Squared Ltd bought a new position in shares of Alignment Healthcare during the fourth quarter valued at $55,000. nVerses Capital LLC bought a new position in shares of Alignment Healthcare during the third quarter valued at $95,000. Ballentine Partners LLC bought a new position in shares of Alignment Healthcare during the fourth quarter valued at $121,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Alignment Healthcare in the third quarter valued at $131,000. Finally, Aigen Investment Management LP acquired a new stake in shares of Alignment Healthcare in the fourth quarter valued at $129,000. 86.19% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ALHC has been the subject of a number of analyst reports. UBS Group upped their price objective on shares of Alignment Healthcare from $9.00 to $12.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. Barclays increased their price objective on Alignment Healthcare from $7.00 to $8.00 and gave the stock an “underweight” rating in a report on Wednesday, October 30th. Stifel Nicolaus increased their price target on Alignment Healthcare from $14.00 to $16.00 and gave the company a “buy” rating in a report on Tuesday, January 14th. Finally, Stephens reiterated an “overweight” rating and set a $17.00 price target on shares of Alignment Healthcare in a report on Thursday, January 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Alignment Healthcare has a consensus rating of “Moderate Buy” and a consensus price target of $11.88.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.